Andexxa Blood Clot Risks Lead to FDA Questions Regarding Safety of the Reversal Agent for Xarelto, Eliquis
Xarelto Side Effects More Likely to Result in Death than Warfarin for Afib Patients with Heart Disease: Study
Side Effects of Blood Thinners, Diabetes Drugs Are Leading Causes of ER Visits Due to Medications: Study
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Xarelto, Pradaxa Bleeding Risks The Same As Warfarin: Study August 7, 2015 Irvin Jackson Add Your Comments New research suggests that the blood thinners Xarelto and Pradaxa are no safer than warfarin when it comes to bleeding and arterial thromboembolic events like heart attacks and strokes. The findings raise further concerns about the new-generation anticoagulants, as they lack an approved reversal agent, which makes it harder for doctors to stop bleeding events that do occur.  In a study published in the American Heart Association’s medical journal Circulation on July 21, researchers from the France’s National Health Insurance Strategy and Research Department report that they found no significant difference in the rate of bleeding events, strokes or heart attacks among patients using either Xarelto, Pradaxa or some form of vitamin K agonist (VKA), which is an older class of blood thinners that includes Coumadin (warfarin). Researchers were specifically looking at the safety and efficacy of the drugs during the early phases of treatment, when patients first begin using them as a preventative measure to avoid strokes caused by nonvalvular atrial fibrillation. The nationwide cohort study used data on 19,713 VKA users, 8,443 Pradaxa users, and 4,651 Xarelto patients. Learn More About Pradaxa Internal Bleeding Lawsuit Side effects of Pradaxa may increase risk of severe bleeding and death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Pradaxa Internal Bleeding Lawsuit Side effects of Pradaxa may increase risk of severe bleeding and death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Pradaxa and Xarelto are two of a group of new blood thinners, often referred to as novel oral anticoagulants (NOACs), which are promoted as superior to warfarin since they require less testing, and are advertised as safer. However, they have come under fire for not being released with a reversal agent, meaning that when bleeding events do occur, doctors often find them hard to stop. The blood thinning effect of warfarin and other vitamin K agonists can be quickly stopped through the use of an antidote. However, doctors have reported more serious bleeding events on Xarelto and Pradaxa, due to the lack of an effective reversal agent. Researchers found no statistically significant difference in the risk of bleeding events or arterial thromboembolism events between any of the three groups for the first 90 days of use. They said that while that appears to back up some claims made by previous studies suggesting that the newer drugs were safe, the findings also raised some concerns specifically due to the lack of a reversal agent, or antidote, and the decision not to monitor patients given Pradaxa and Xarelto. “NOAC cannot be considered to be safer than VKA during the early phase of treatment,” the researchers concluded. “On the contrary, the clinical implications of our results are that physicians must be just as cautious when initiating NOAC as when initiating VKA, particularly in view of the absence of an antidote and objective monitoring of the extent of anticoagulation.” New Blood Thinner Bleeding Risks Pradaxa was introduced by Boehringer Ingelheim in late 2010 as the first member of a new class of anticoagulants. Xarelto was introduced by Bayer and Janssen Pharmaceuticals in 2011, as the second member of this class. While all blood thinners carry a risk of bleeding injury, Pradaxa and Xarelto have been linked to a surprising number of problems as more and more patients are switched from warfarin to the new anticoagulants. In addition to the lack of a reversal agent, several recent studies have also raised questions about the marketing claims made by the makers of these new anticoagulants, suggesting that blood monitoring may actually help doctors identify patients at the greatest risk of bleeding. In July 2014, an investigative report published by The BMJ suggested that the makers of Pradaxa failed to provide the FDA with important clinical trial data that suggested users may benefit from regular blood monitoring to make sure the drug did not build up in their bloodstream, increasing the risk of bleeds. In another study published by the Journal of Cardiology in October 2014, researchers indicated that Xarelto monitoring may have helped doctors understand the effects of the drug on a particular patient and their associated bleeding risk. Boehringer Ingelheim faced more than 4,000 Pradaxa lawsuits that allege inadequate warnings were provided about the lack of an available reversal agent for their medication. Following several years of litigation, the drug maker agreed to pay $650 million in Pradaxa settlements last year, with an average of about $150,000 awarded to former users who experienced injuries associated with uncontrollable bleeds. Xarelto (rivaroxaban) was the second member of this new class of anticoagulants to be approved by the FDA, hitting the market about a year after Pradaxa. However, as Boehringer Ingelheim faced mounting lawsuits and publicity over severe bleeding events associated with Pradaxa, Xarelto has overtaken the top spot among the new medications, with sales exceeding those of Pradaxa in 2013. A growing number of Xarelto bleeding lawsuits are now being pursued on behalf of former users, raising similar allegations that inadequate warnings were provided about the lack of an approved reversal agent and claiming that the drug makers should have never introduced the medication without an antidote to allow doctors to reverse bleeding events. Tags: Atrial Fibrillation, Bleeding, Blood Thinners, Coumadin, Heart Attack, Pradaxa, Stroke, Warfarin, Xarelto More Pradaxa Lawsuit Stories Andexxa Blood Clot Risks Lead to FDA Questions Regarding Safety of the Reversal Agent for Xarelto, Eliquis November 21, 2024 Xarelto Side Effects More Likely to Result in Death than Warfarin for Afib Patients with Heart Disease: Study September 1, 2022 Side Effects of Blood Thinners, Diabetes Drugs Are Leading Causes of ER Visits Due to Medications: Study October 15, 2021 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES 6 Bard PowerPort Lawsuits Selected for Bellwether Trials in Federal MDL (Posted: today) A federal judge has identified the six Bard PowerPort lawsuits that will serve as the first bellwether trials, to test allegations that the port catheters were defectively designed. MORE ABOUT: BARD POWERPORT LAWSUITCourt Indicates Bard PowerPort MDL Bellwether Lawsuits Should Include 3 Infection, 2 Thrombosis and 1 Fracture Case (05/06/2025)Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (04/30/2025)Bard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025) MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 3 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025) Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: 4 days ago) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)
Andexxa Blood Clot Risks Lead to FDA Questions Regarding Safety of the Reversal Agent for Xarelto, Eliquis November 21, 2024
Xarelto Side Effects More Likely to Result in Death than Warfarin for Afib Patients with Heart Disease: Study September 1, 2022
Side Effects of Blood Thinners, Diabetes Drugs Are Leading Causes of ER Visits Due to Medications: Study October 15, 2021
6 Bard PowerPort Lawsuits Selected for Bellwether Trials in Federal MDL (Posted: today) A federal judge has identified the six Bard PowerPort lawsuits that will serve as the first bellwether trials, to test allegations that the port catheters were defectively designed. MORE ABOUT: BARD POWERPORT LAWSUITCourt Indicates Bard PowerPort MDL Bellwether Lawsuits Should Include 3 Infection, 2 Thrombosis and 1 Fracture Case (05/06/2025)Lawyers Proposed 11 Bard Implantable Port Catheter Lawsuits as Bellwether Trial Candidates (04/30/2025)Bard PowerPICC Intravascular Catheter Leaks Linked to Reports of Serious Injuries: FDA (04/21/2025)
MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 3 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)
Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: 4 days ago) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)